U.s. food and drug administration awards $2.6 million orphan products development grant for expanded study of hybryte™ in the treatment of cutaneous t-cell lymphoma

Grant supports study of expanded hybryte™ treatment, including in the home use setting princeton, n.j. , sept. 6, 2022 /prnewswire/ -- soligenix, inc. (nasdaq: sngx) (soligenix or the company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the u.s. food and drug administration (fda) has awarded an orphan products development grant to support the evaluation of hybryte™ (synthetic hypericin) for expanded treatment in patients with early-stage ctcl.
SNGX Ratings Summary
SNGX Quant Ranking